Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 3 news outlets
twitter: 9 X users

patent: 3 patents
facebook: 1 Facebook page

Citations

dimensions_citation: 188 Dimensions

Readers on

mendeley: 158 Mendeley

Summary News X Patents Facebook Dimensions citations

So far, Altmetric has seen 4 news stories from 3 outlets.

ImmunID, Memorial Sloan Kettering to Validate Cancer Immunotherapy Companion Dx

Genomeweb, 23 Feb 2016

NEW YORK (GenomeWeb) – French companion diagnostics firm ImmunID announced today that it has signed a deal with Memorial Sloan…

With Global IP Secured, ImmunID Outlines Plans for PCR-Based Cancer Companion Test Market

Genomeweb, 18 Dec 2015

NEW YORK (GenomeWeb) – ImmunID announced this week it has obtained patent protection in China, adding to IP in Europe, Japan…

Des données montrant l'utilité clinique d'ImmunTraCkeR® pour la prédiction de réponse aux inhibiteurs de point de contrôle immunitaire ont été publiées dans le Journal for ImmunoTherapy of Cancer

La Gazette du Laboratorie, 17 Jul 2015

Data Advancing the Clinical Utility of ImmunID's ImmunTraCkeRÂ for Prediction of Response to Immune Checkpoint Inhibitors Published in the Journal for ImmunoTherapy of Cancer

Bioportfolio, 07 Jul 2015

GRENOBLE France July 7 2015 PRNewswire &160;ImmunID today announced the publication of a short report in the Journal for…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.